EcoDrugPlus

B-Raf Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSACLG00000013512
Gene Symbol: BRAF
3 Cross references
220 Possible Orthologues:

B1 Bradykinin Receptor-Like

Ensembl ID : ENSACLG00000014110
Gene Symbol: LOC113012055
3 Cross references
149 Possible Orthologues:

Bcl2 Apoptosis Regulator

Ensembl ID : ENSACLG00000022493
Gene Symbol: BCL2
3 Cross references
172 Possible Orthologues:

Bcl2 Like 1

Ensembl ID : ENSACLG00000007126
Gene Symbol: BCL2L1
3 Cross references
229 Possible Orthologues:

Bcl2 Like 10

Ensembl ID : ENSACLG00000014449
Gene Symbol: BCL2L10
1 Cross references
129 Possible Orthologues:

Bcr Activator Of Rhogef And Gtpase

Ensembl ID : ENSACLG00000021060
Gene Symbol: BCR
3 Cross references
209 Possible Orthologues:

Bruton Tyrosine Kinase

Ensembl ID : ENSACLG00000002214
Gene Symbol: BTK
3 Cross references
204 Possible Orthologues:

C-C Chemokine Receptor Type 9-Like

Ensembl ID : ENSACLG00000016197
Gene Symbol: LOC113011255
2 Cross references
190 Possible Orthologues:

C-C Motif Chemokine Receptor 9

Ensembl ID : ENSACLG00000005006
Gene Symbol: CCR9
3 Cross references
194 Possible Orthologues:

C-X-C Chemokine Receptor Type 2-Like

Ensembl ID : ENSACLG00000005533
Gene Symbol: LOC113007958
2 Cross references
275 Possible Orthologues:

C-X-C Motif Chemokine Receptor 4

Ensembl ID : ENSACLG00000021741
Gene Symbol: CXCR4
3 Cross references
216 Possible Orthologues:

C-Reactive Protein-Like

Ensembl ID : ENSACLG00000015991
Gene Symbol: LOC113037489
2 Cross references
355 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).